istock-840333528_phonlamaiphoto
PhonlamaiPhoto / iStockphoto.com
13 June 2018Americas

Chinese company fund invests in AI specialist

China-based pharmaceutical technology company WuXi AppTec has partnered with artificial intelligence (AI) specialist Insilico Medicine to integrate Insilico’s AI technology with WuXi’s laboratory infrastructure.

Baltimore-based Insilico, which specialises in the application of deep learning for target identification, drug discovery and aging research, announced the completion of a round of funding led by WuXi’s corporate venture fund on Monday, June 11.

The funding is intended to boost Insilico’s work in approaches to generating novel molecules, as well as expand a variety of biomarker initiatives.

Ge Li, chairman of WuXi, said that the companies share a mutual vision that AI and machine learning will optimise the drug discovery process by increasing the probability of success at the pre-clinical level.

Edward Hu, chief financial officer and chief investment officer of WuXi, added: “We have been looking to collaborate with AI-enabled technologies to enhance the drug discovery and development process.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Big Pharma
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.

More on this story

Big Pharma
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.